Comparison of long-term immunogenicity (23 y) of 10 μg and 20 μg doses of hepatitis B vaccine in healthy children

Hepatitis B (HB) vaccine induces protective levels of antibody response (anti-HBs 10 mIU/mL) in 90-99% of vaccinees. The levels of anti-HBs antibody decline after vaccination. The aim of this study was to evaluate the persistence of anti-HBs antibodies and immunologic memory in healthy adults at 20 years after primary vaccination with recombinant HB vaccine. Blood samples were collected from 300 adults at 20 years after primary HB vaccination and their sera were tested for anti-HBs antibody by ELISA technique. A single booster dose of HB vaccine was administered to a total of 138 subjects, whose anti-HBs antibody titer was <10 mIU/mL. The sera of subjects were retested for the anti-HBs antibody levels at 4 weeks after booster vaccination. At 20 years after primary vaccination 37.0% of participants had protective levels of antibody with geometric mean titer (GMT) of 55.44 § 77.01 mIU/mL. After booster vaccination, 97.1% of vaccinees developed protective levels of antibody and the GMT rose from 2.35 § 6.49 mIU/mL to 176.28 § 161.78 mIU/mL. 125/138 (90.6%) of re-vaccinated subjects also showed an anamnestic response to booster vaccination. At 20 years after primary vaccination with HB vaccine, low proportion of the subjects had protective levels of antibody. However, the majority of the re-vaccinated subjects developed protective levels of anti-HBs and showed an anamnestic response after booster vaccination. Additional follow-up studies are necessary to determine the duration of immunological memory.

Section: 21mentioning

confidence: 73%

“…14,19 All participants were basically healthy, with no acute or chronic illnesses. Indeed each individual with history of chronic or acute disease and use of any drug were excluded from the study.…”

Section: Methodsmentioning

confidence: 99%

The persistence of anti-HBs antibody and anamnestic response 20 years after primary vaccination with recombinant hepatitis B vaccine at infancy

Bagheri-Jamebozorgi

Keshavarz

Nemati

et al. 2014

“…Vaccines are one of the most useful public health interventions for combating infectious diseases, 19 and the hepatitis B vaccine is the most effective prevention for HBV infection. 20 As such, we also sought to assess whether people who had received the hepatitis B vaccination might exhibit lower levels of HBV-related discrimination.…”

Section: Introductionmentioning

confidence: 99%

Hepatitis B-related knowledge and vaccination in association with discrimination against Hepatitis B in rural China

Wang

Zhu

et al. 2015

Hepatitis B virus (HBV) remains a challenging public-health issue in China. Hepatitis B carriers and patients suffer not only physically but also experience strong discrimination and stigma. China's rural population is 629 million. Thus, there is a great need to understand the situation surrounding HBV-related discrimination in everyday life in rural China. We studied 6,538 participants (18 y old) from 42 villages across 7 provinces (districts). Many studies have addressed discrimination against those with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). However, few studies have addressed HBV-related discrimination. We found that the fear of HBV infection, not lack of knowledge about it, predominantly leads to HBV-related discrimination (although limited knowledge is also a cause). Notably, receiving the HBV vaccination contributes to reduced discrimination. In addition, the existence of fewer misunderstandings about false HBV transmission routes plays a more important role in discrimination than does understanding of true HBV transmission routes. Therefore, to reduce HBV-related discrimination, policy makers should consider eliminating HBV-related fear, strengthening adult HBV immunization programs, developing large-scale education dissemination about HBV transmission routes and non-transmission routes, and paying greater attention to target populations.

“…Our previous vaccine intervention trial also demonstrated that both 10 mg and 20 mg doses could elicit similar protective response lasting for 11 y In the current study, the long-term immunogenicity and serological protection rates in both 10 mg and 20 mg dose plasma-derived HepB groups were similar during 23 y of follow-up in participants from highly HBV-endemic areas. 63 No significant differences between these vaccinated groups were identified during this study. This result was consistent with the findings from previous research studies.…”

Section: Discussionmentioning

confidence: 88%

24 year outcomes of hepatitis B vaccination in Hangzhou, China

Xu²,

Wang³

et al. 2015

To evaluate the impact of the universal infant HepB vaccination program on hepatitis B virus infection in Hangzhou, China. Hepatitis B incidences and HepB vaccination rates of Hangzhou from 1990 to 2003 were acquired from the historical paper-documents, while which were derived from China Information System for Diseases Control and , P < 0.001). Significant association was found between incidence of hepatitis B and HepB vaccination rate (r D 0 .946, x 2 D 11.813, P for trend D 0.001). A total of 5605 participants aged 0-59 y included in this serological survey. The prevalence of HBsAg, anti-HBs, anti-HBc, HBeAg and anti-HBe were 6.19%, 45.83%, 57.25%, 0.62%, and 4.37%, respectively. Hangzhou has successfully integrated the HepB into routine immunization programs and this has had a significant impact on decreasing the incidence of hepatitis B infection.